HIMS slides around 9.5% as shift to GLP-1 drugs and margin contraction drive selloff

Traders Union
All News
Stocks
Hims & hers slides 9.44% today

Highlights

Hims & Hers Health reported Q3 2026 revenue of $890.4 million, up 49% year over year but missing forecasts, with a net loss of $0.14 per share.
Gross margin declined sharply to 57% from 74% a year earlier, driven by higher costs for branded GLP-1 offerings and increased international investments.
Shares of Hims & Hers Health are trading below key moving averages with bearish technical momentum, and the expected price range over the next five days is $17.87 to $23.67.

Margin slump and net loss as revenue growth fails to offset costs

Hims & Hers Health reported Q3 2026 revenue of approximately $890.4 million, reflecting a 49% year-over-year increase, but slightly missing analyst forecasts. The company experienced a sharp decline in gross margin to 57% from 74% a year earlier, with management citing higher costs due to expanding branded GLP-1 weight-loss offerings and significant international investments, as rest-of-world revenue reached $233 million. Net income turned into a loss of $0.14 per share, with reduced full-year revenue and EBITDA guidance, and subscriber growth moderated to nearly 2.8 million. Hims & Hers also emphasized ongoing international growth, expansion of therapeutic offerings, and investments in AI and pharmacy infrastructure.

Anton Kharitonov, expert at Traders Union, sees Hims & Hers Health in a vulnerable technical and fundamental position. He notes the drop below all key moving averages, which corroborates the downside pressure. Margin erosion and a swing to net loss highlight deteriorating business quality. Lowered guidance and moderating subscriber growth reinforce the negative sentiment. Signals from momentum and oversold indicators do not yet invalidate the bearish trend. "The stock remains under clear selling pressure, and any short-term bounces are likely to be unsustainable at this stage."

Viktoras Karapetjanc, expert at Traders Union, maintains an optimistic view despite market volatility. He highlights that Hims & Hers posted strong double-digit revenue growth and expanded its global footprint, showcasing underlying business momentum. Significant investment in branded therapies and tech infrastructure lays groundwork for long-term value creation. Karapetjanc argues that international revenue strength and expanding therapeutic offerings position the firm for future upside once near-term headwinds abate. "In my view, strategic investments now create a positive setup for medium-term recovery as global demand accelerates."

Sholanke Dele, market strategist, sees risk dominating the outlook for Hims & Hers. He flags the steep decline in gross margin and restates that net income has fallen into negative territory. Lowered guidance points to fragile fundamentals and bearish investor sentiment. "For me, persistent margin pressure and weak momentum keep the downside in play for now."

Sustained selling pressure amid bearish momentum and oversold signals

Hims & Hers Health is currently trading below the 20-day, 50-day, and 200-day moving averages ($27.55, $28.31, and $26.87 respectively), pointing to continued selling pressure and a bearish alignment in both short- and long-term trends. The strongest immediate resistance stands at $22.81, with a near-term support floor at $17.87 based on the current forecast band. Momentum indicators reflect a clear negative bias: the MACD signals ongoing bearish momentum and the Average Directional Index (ADX) remains low, suggesting a weak trend. The Relative Strength Index (RSI) is neutral, but both the Stochastic RSI and Commodity Channel Index (CCI) are in their respective oversold zones, indicating possible selling exhaustion, though Bull/Bear Power (BBP) and the Awesome Oscillator both confirm continued bearish momentum.

Earlier, analysts noted that Hims & Hers Health faced persistent downside momentum following weaker profitability and reduced guidance, underscoring a bearish technical setup. The latest results reinforce this outlook, with traders advised to monitor the $17.87 support as a key inflection point for imminent downside risk.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.